Adam Bisaga
New York State Psychiatric Institute · Columbia University · Columbia University and NYSPI
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Adam Bisaga as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 20:24 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05382091 · Evaluation of the O'Neil Long Acting Naltrexone Implant in Opioid Dependent PersonsGo Medical Industries Pty Ltd · not yet recruiting · Opioid Use Disorder · principal investigator
- Ph2/Ph3NCT05011266 · Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use DisorderNew York State Psychiatric Institute · recruiting · Opioid-use Disorder · principal investigator
- Ph1NCT04716881 · Pharmacokinetic Study of Vivitrol in Healthy ParticipantsGo Medical Industries Pty Ltd · completed · Opioid-use Disorder · principal investigator
- Ph1NCT03810495 · The O'Neil Long Acting Naltrexone Implant (OLANI) Pharmacokinetic (PK)/Safety Study in Healthy VolunteersGo Medical Industries Pty Ltd · completed · Opioid Use Disorder · principal investigator
- Ph2/Ph3NCT01468012 · Imaging the Neurobiology of Behavioral and Medication Treatment for Cocaine DependenceNew York State Psychiatric Institute · completed · Cocaine Dependence · principal investigator
- Ph1NCT01437293 · Behavioral and Physiological Effects of Cocaine in Cocaine-dependent Participants Treated With Levodopa in Combination With Carbidopa and Entacapone (LCE)New York State Psychiatric Institute · completed · Cocaine Abuse · principal investigator
- Ph1NCT01377610 · Improved Strategies for Outpatient Opioid DetoxificationNew York State Psychiatric Institute · completed · Opioid Dependence · principal investigator
- Ph2/Ph3NCT01024335 · Dronabinol Naltrexone Treatment for Opioid DependenceNew York State Psychiatric Institute · completed · Opioid Dependence · principal investigator
- Ph2NCT00731055 · Effects of Varenicline on Cigarette Self AdministrationNew York State Psychiatric Institute · completed · Nicotine Dependence · principal investigator
- Ph2/Ph3NCT00476242 · Memantine as a Supplement to Naltrexone in Treating Heroin DependenceNew York State Psychiatric Institute · completed · Opioid Dependence, Heroin Dependence · principal investigator
- Ph1NCT00136786 · Effect of Memantine Versus Bupropion on Smoking Relapse in Nicotine-Dependent Individuals - 3New York State Psychiatric Institute · completed · Tobacco Use Disorder · principal investigator
- Ph1NCT00136747 · The Effects of Memantine and Bupropion on Acute, Reinforcing, and Conditioned Effects of Cigarettes - 1New York State Psychiatric Institute · completed · Tobacco Use Disorder · principal investigator
- N/ANCT00136838 · Effect of Smoking Exposure on Smoking Relapse Following Brief Abstinence - 2New York State Psychiatric Institute · completed · Tobacco Use Disorder · principal investigator
- Ph2NCT00125515 · Memantine and Naltrexone Treatment for Opioid DependenceNew York State Psychiatric Institute · completed · Opioid Dependence · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 20:24 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Efficacy of buprenorphine and XR-naltrexone combination for relapse prevention in opioid use disorderU01DA046430 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · fiscal years 2020 to 2026 · $695,203 awarded in 2026Grant number is on one of their registry trials
- Evaluation of safety and pharmacokinetics of naltrexone implantUH3DA047720 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · fiscal years 2021 to 2023 · $3,864,542 awarded in 2023Grant number is on one of their registry trials
- Evaluation of safety and pharmacokinetics of naltrexone implantUG3DA047720 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · fiscal years 2018 to 2019 · $3,713,497 awarded in 2019Grant number is on one of their registry trials
- A Strategy to Improve Success of Treatment Discontinuation in Buprenorphine RespondersR21DA042243 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · fiscal years 2017 to 2018 · $192,375 awarded in 2018Same name and institution; not confirmed by an ID
- Improved Strategies for Outpatient Opioid DetoxificationR01DA030484 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · fiscal years 2014 to 2015 · $652,661 awarded in 2015Same name and institution; not confirmed by an ID
- Training and Education CoreU54DA037842 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · fiscal years 2014 to 2015 · $186,760 awarded in 2015Same name and institution; not confirmed by an ID
- Pioglitazone for the Treatment of Opioid and of Nicotine DependenceR01DA031022 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · fiscal years 2010 to 2013 · $833,527 awarded in 2013Same name and institution; not confirmed by an ID
- Dronabinol naltrexone treatment for opioid dependenceR01DA027124 · NIDA · COLUMBIA UNIVERSITY HEALTH SCIENCES · fiscal years 2009 to 2010 · $402,500 awarded in 2010Grant number is on one of their registry trials
- Memantine Naltrexone Treatment for Opioid DependenceR01DA015822 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · fiscal years 2005 to 2009 · $555,581 awarded in 2009Grant number is on one of their registry trials
- Developing Medication For Tobacco Addiction: NMDA AgentsR01DA017572 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · fiscal years 2003 to 2007 · $380,437 awarded in 2007Grant number is on one of their registry trials
- EVALUATION OF NMDA ANTAGONIST FOR OPIATE DEPENDENCEK23DA000429 · NIDA · COLUMBIA UNIVERSITY HEALTH SCIENCES · fiscal years 1999 to 2003 · $176,666 awarded in 2003Grant number is on one of their registry trials
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Novel Medication Approaches for Substance AbuseP50DA009236 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI Herbert David Kleber · fiscal years 1994 to 2013Named on NCT01437293
- Opiate Dependence: Combined Naltrexone/Behavior TherapyR01DA010746 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI Maria A Sullivan · fiscal years 1997 to 2008Named on NCT01377610
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 20:24 UTC. The ranking covers the 200 most relevant of 41 PubMed records, and a shared surname and initials can bring in a namesake. All 41 on PubMed
- The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans.Psychopharmacology (Berl) · 2001102 citationsRCR 3.0
- The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone.Drug Alcohol Depend · 201576 citationsRCR 3.8
- Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine.Am J Psychiatry · 201774 citationsRCR 4.2
- Acute effects of memantine in combination with alcohol in moderate drinkers.Psychopharmacology (Berl) · 200473 citationsRCR 2.2
- A randomized placebo-controlled trial of gabapentin for cocaine dependence.Drug Alcohol Depend · 200669 citationsRCR 2.2
- Dronabinol and lofexidine for cannabis use disorder: A randomized, double-blind, placebo-controlled trial.Drug Alcohol Depend · 201666 citationsRCR 3.2
- A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder.Am J Psychiatry · 201966 citationsRCR 4.0
- Extended-release mixed amphetamine salts and topiramate for cocaine dependence: a randomized controlled trial.Biol Psychiatry · 201265 citationsRCR 2.5
- Interaction between naltrexone and oral THC in heavy marijuana smokers.Psychopharmacology (Berl) · 200359 citationsRCR 1.9
- 58 citationsRCR 2.4